Life Technologies’ lentiviral vector technology will be leveraged in the development of next generation upcyte cells for biopharma and academic research markets.
Medicyte CEO Dr. Joris Braspenning said, "With the technology we have licensed from Life Technologies, we are capable to bring more predictive, reliable, and standardized cell strains on the market."
Several studies revealed the quantity as well as quality benefits of the company’s upcyte hepatocytes.
Further comparable results to primary cells in in-vitro assays including CYP 3A4-Induction, genotoxicity or hepato- and cytotoxicity will be demonstrated by the next generation upcyte cells.
Financial details of the deal have not been revealed.